04 Small Animal Imaging Facility

项目摘要：小动物成像设施(SAIF) 小动物成像设施(SAIF)的使命是通过提供癌症来促进癌症研究 中心成员拥有强大的成像技术和成功整合所需的专业知识 将影像科学纳入临床前癌症研究。约翰·D·哈泽尔博士担任主任，詹姆斯·A·A博士担任主任。 班克森担任联席董事。该设施包括教员专家、受过专门培训的工作人员和最先进的设备 成像仪器，其中大部分在癌症中心的其他地方是没有的。赛义夫有3辆 在校园内分开设置站点，以确保能够方便地访问所有癌症中心成员。赛义夫成像 实验室位于北校区，毗邻小动物的，在里面 南校区Varium和南校区研究大楼#3。赛义夫教职员工有空 支持临床前癌症研究中成像的方方面面，从提案和实验设计到 数据采集、分析、解释和展示。目前，赛义夫拥有21个独特的成像部件 为小动物优化的设备和全套支持动物的辅助设备 实验前、实验中和实验后。成像设备包括3台高场磁共振 扫描仪、低场永磁体磁共振扫描仪、动态核极化系统 为了产生超极化磁共振试剂，一种微型计算机断层扫描系统，正电子 发射断层扫描/单光子发射计算机断层扫描/计算机断层扫描扫描仪，2台小型 动物辐射研究平台，2个超声系统(1个能够进行光声成像)，一个专用 光声成像系统、1个机柜X射线系统、6个光学成像系统和1个原型机 松弛测量系统(作为研究协议的一部分借出)。在此赠款期间，MD Anderson资助了 5,918,344美元的资本设备，通过NCI共享或高端获得了约110万美元 仪器设备补助。年度运营资金为195,521美元(20%)来自CCSG，719,742美元(74%)来自CCSG 计划收入，以及53,413美元(6%)的机构支助。在这6年的赠款期间，赛义夫担任了一名 共有250名癌症中心成员，包括来自CCSG所有16个项目的研究人员。总共87%的人 使用是由同行审查资助的，SAIF要求CCSG提供200,057美元(20%)的赠款Yr44。总括 42年的使用量比前一个供资周期的平均使用量增加了2.7倍。SAIF支持181 在本报告所述期间，有51份(28%)经同行评议的出版物在有IF&>10和119份的期刊上发表 (66%)发表在IF&GT；5中。具体目标是：目标1：保持广泛的最新水平 支持癌症中心临床前成像需求的成像仪器和敬业的工作人员 成员；目标2：在规划、获取和分析方面提供咨询、培训和支持 成像数据；和目标3：开发和实施新的技术和方法，以提高准确性 以及临床前癌症研究中定量成像生物标志物的精确度。

PROJECT SUMMARY: SMALL ANIMAL IMAGING FACILITY (SAIF) The mission of the Small Animal Imaging Facility (SAIF) is to advance cancer research by providing cancer center members with powerful imaging technologies and the expertise necessary to successfully integrate imaging sciences into preclinical cancer research. Dr. John D. Hazle serves as director, and Dr. James A. Bankson serves as co-director. The facility includes faculty experts, specially trained staff, and state-of-the-art imaging instrumentation, most of which is not available anywhere else in the cancer center. The SAIF has 3 separate sites across the campus to ensure convenient access to all cancer center members. SAIF imaging laboratories are located on the North Campus adjacent to and contiguous with the small animal vivarium, inside the South Campus Vivarium, and in South Campus Research Building #3. SAIF faculty and staff are available to support all aspects of imaging in preclinical cancer research, from proposal and experiment design through data acquisition, analysis, interpretation, and presentation. Currently, the SAIF has 21 unique pieces of imaging equipment optimized for small animals and a full complement of ancillary equipment for support of animals before, during, and after experiments. The imaging equipment includes 3 high-field magnetic resonance scanners, a low-field permanent magnet magnetic resonance scanner, a dynamic nuclear polarization system for generating hyperpolarized magnetic resonance agents, a microcomputed tomography system, a positron emission tomography/single-photon emission computed tomography/computed tomography scanner, 2 small- animal radiation research platforms, 2 ultrasound systems (1 capable of photoacoustic imaging), a dedicated photoacoustic imaging system, a cabinet X-Ray system, 6 optical imaging systems, and a prototype magnetic relaxometry system (on loan as part of a research agreement). During this grant period, MD Anderson has funded $5,918,344 in capital equipment, and approximately $1.1M has been obtained through NCI Shared or High-end Instrumentation grants. Annual operational funding is $195,521 (20%) from the CCSG, $719,742 (74%) from program income, and $53,413 (6%) of institutional support. During this 6-year grant period, the SAIF served a total of 250 cancer center members, including investigators from all 16 CCSG programs. A total of 87% of all usage was peer-review funded, and the SAIF is requesting $200,057 (20%) from the CCSG in grant Yr44. Overall use has increased 2.7-fold in Yr42 over the average use in the prior funding cycle. The SAIF supported 181 peer-reviewed publications during this reporting period, with 51 (28%) published in journals with IF >10 and 119 (66%) published in those with IF >5. The specific aims are: Aim 1: To maintain a broad range of state-of-the-art imaging instrumentation and dedicated staff that support the preclinical imaging needs of cancer center members; Aim 2: To provide consultation, training and support in the planning, acquisition, and analysis of imaging data; and Aim 3: To develop and implement new technologies and methods that improve the accuracy and precision of quantitative imaging biomarkers in preclinical cancer research.